Clinical Trials
Zilovertamab Vedotin + SOC in participants with DLBCL
Disease Type: Lymphoma
A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003)
Locations
Alleghany , Blacksburg , Roanoke , Salem , Wytheville